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Abstract
Background: Currently, there is no agreed standard for exploring the antimicrobial activity of wound antiseptics in
a phase 2/ step 2 test protocol. In the present study, a standardised in-vitro test is proposed, which allows to test
potential antiseptics in a more realistically simulation of conditions found in wounds as in a suspension test.
Furthermore, factors potentially influencing test results such as type of materials used as test carrier or various
compositions of organic soil challenge were investigated in detail.
Methods: This proposed phase 2/ step 2 test method was modified on basis of the EN 14561 by drying the
microbial test suspension on a metal carrier for 1 h, overlaying the test wound antiseptic, washing-off, neutralization,
and dispersion at serial dilutions at the end of the required exposure time yielded reproducible, consistent test results.
Results: The difference between the rapid onset of the antiseptic effect of PVP-I and the delayed onset especially of
polihexanide was apparent. Among surface-active antimicrobial compounds, octenidine was more effective
than chlorhexidine digluconate and polihexanide, with some differences depending on the test organisms.
However, octenidine and PVP-I were approximately equivalent in efficiency and microbial spectrum, while
polihexanide required longer exposure times or higher concentrations for a comparable antimicrobial efficacy.
Conclusion: Overall, this method allowed testing and comparing differ liquid and gel based antimicrobial
compounds in a standardised setting.
Keywords: PVP-iodine, Chlorhexidine digluconate, Polyhexanide, Octenidine dihydrochloride, EN 14561,
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Background and objectives
The potential antimicrobial activity can be tested follow-
ing the European Norm EN 1040 (bactericidal activity)
and EN 1275 (fungicidal and yeasticidal activity) [1, 2],
both quantitative suspension tests without organic chal-
lenge. If a tested compound fails this phase 1 basic test,
further investigations on its suitability as a biocide are fu-
tile. If, however, this phase 1 basic test is passed success-
fully, further tests simulating clinically relevant organic
soil challenges (phase 2/ step 1 tests such as EN 13727 [3],
a quantitative suspension test for the evaluation of bacteri-
cidal activity in the medical area) are required in order to
assess the usability with simulated bioburden, which is
recommended for application on mucous membranes
with 10% albumin, 10% sheep blood, 1% mucin, or their
combination, and for conditions representative for
wounds with 10% albumin or 10% sheep blood challenge
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[4], or, maybe more representative for conditions on
chronic wounds, Eagle’s Minimal Essential Medium
(MEM) with Earle’s salts and L-glutamine, supple-
mented with 10% fetal calf serum without addition of
antibiotics [5].
In the next step, so-called phase 2/ step 2 tests, stan-
dardised in-vitro carrier tests with and without organic
soil exist for testing instrument disinfectants, e.g. EN
14561 bactericidal activity and EN 14562 (fungicidal and
yeasticidal activity) [6, 7]. Yet, there is no agreed stand-
ard for exploring the antimicrobial activity of potential
wound antiseptics in a phase 2/ step 2 test protocol.
Previous attempts to apply the test conditions of the
European standards EN 14561 and EN 14562 for testing
the antimicrobial efficacy of wound antiseptics on test
disc carriers have successfully been conducted with med-
ical honey and silver wound dressings [8, 9]. However,
despite the general feasibility of disc carriers for testing
wound antiseptics following a modification of the phase
2/ step 2 tests EN 14561 and EN 14562, currently there
is no recommendation regarding the required effective-
ness of wound antiseptics within the declared exposure
time in the carrier test. To solve this problem, Ebert
et al. have used a significant difference from the control
as criterion for sufficient antiseptic effectiveness [9].
Considering the recommended efficacy for instrument
disinfectants of ≥ 5 log10 or ≥ 4 log10 reduction within
the declared exposure time against bacteria and yeasts
(referred as reduction factor “RF”) [10], a plausible rec-
ommendation for wound antiseptics would be an log10
RF ≥ 5 without, and ≥ 3 with organic soil challenge. Aside
of criteria for test interpretation, a number of other fac-
tors potentially influencing test results, such as suitabil-
ity of different surface materials used as test carriers, the
reproducibility of results using different antimicrobial
compounds frequently used as wound antiseptics such
as PVP-iodine (PVP-I), chlorhexidine digluconate (CHG),
octenidine dihydrochloride (OCT), or polihexanide
(PHMB), or selection of a reference compound as stand-
ard reference for future testing have not been explored. In
the present study, the possible influence of such factors is
investigated in detail.
Materials and methods
The following test organisms were selected for all exper-
iments: Staphylococcus aureus (ATCC 6538), Entero-
coccus faecium (ATCC 6057), and Pseudomonas
aeruginosa (ATCC 15442). Testing of the influence of
different carrier disc materials was conducted with P.
aeruginosa only. Furthermore, OCT and PHMB were
additionally tested against Staphylococcus epidermidis
(ATCC 12228), Serratia marcescens (ATCC 13880), and
Candida albicans (ATCC 10231).
PVP-I and CHG were tested as aqueous solutions
made from poly(vinylpyrrolidone)-Iodine Complex 100%
(CAS 25655-41-8, Sigma-Aldrich®) in a final concentra-
tion of 10% PVP-I, and 20% Chlorhexidine digluconate
(CAS 18472-51-0, Sigma-Aldrich®). OCT and PHMB
were tested as commercially available gels, manufactured
by Schülke and Mayr GmbH (Norderstedt, Germany)
under GLP conditions consisting of the following ingre-
dients: 2.85% Glycerol 85%, 94.65% deionized water and
2.5% hydroxyethyl cellulose. OCT was tested in dilutions
between 0.005, and 0.1%, PHMB was tested in dilutions
of 0.02, 0.04, and 0.1%.
To determine the potential influence of different ma-
terial used as test carriers, circular metal test carriers
(diameter 20 mm, 1.2 mm thick) were made of stainless
steel (1.4301 according to EN 10088–1, surface finish
quality 2B on top and bottom according EN 10088–2;
Cziotec GmbH, Greifswald, Germany), circular plastic
carriers (diameter 12.7 mm, 3.0 mm thick) were made of
polycarbonate (BioSurface Technologies Corp., Montana,
USA), and for glass carriers, microscope examination
slides were cut to a size of 26 mm × 26 mm (following
ISO 8037/I; Glasbearbeitungswerk GmbH & Co. KG,
Braunschweig, Germany).
For the production of microbial test solutions, a frozen
bead with adherent organisms of the respective micro-
bial test strain was taken from an overnight culture,
transferred onto blood agar and incubated for 24 h at
36 °C ± 1 °C. For the final tests, 4 colony forming units
(cfu) were dispersed in 30 mL of Eagle’s Minimal Essential
Medium (MEM) with Earl’s salts and L- glutamine (PAA
Laboratories, Germany) supplemented with 10% foetal bo-
vine serum (FBS; Gibco) (MEM+ FBS). 30 min prior to
the start of a test, human erythrocytes were added to the
suspension, yielding an organic blood soil of 30%.
The experimental setup was based on requirements of
EN 14561 [6]. Disk carriers were placed in Petri dishes
coated with 0.05 mL of test suspension and dried for
60 min in a workbench under laminar airflow. Then,
0.25 mL of test compound (solution or gel) was applied
to the respective test carrier surfaces, assuring, that they
covered the dried test suspension completely. Sterile dis-
tilled water or the basic gel without antimicrobial com-
pound were used as negative controls in parallel. After
5 min, 30 min, 3 h, 10 h, and 24 h, the test carriers were
placed in 10 mL test tubes (Greiner Bio-One GmbH,
Frickenhausen, Germany), previously filled with 5 mL of
sterile glass beads and 10 mL of neutralizing agent. Test
tubes were then vortexed for 10 min. Serial dilutions of
the resulting mixture were prepared in tryptone + 0.89%
NaCl solution. Thereafter, volumes of 0.1 mL in at least
two different dilutions were applied on Tryptone soy
agar (TSA) in parallel. After 48 h of incubation at 36 °C
± 1 °C, the resulting colony forming units (cfu) were
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counted and the reduction factor (RF) was calculated ac-
cording to the formula: log10 RF = lg (cfu1) - lg (cfu2),
giving the log10 RF for the tested exposure time. Cfu1
denotes the number of cfu/mL not exposed to the sam-
ple (negative control), and cfu2 denotes the number of
cfu/mL after exposure to the sample.
All neutralizing agents were tested and validated fol-
lowing EN 1040 and EN 1275. A mixture of 4% tween
80, 3% saponin, 0.4% lecithin, and 1% sodium dodecyl
sulphate (SDS) in 1 l of distilled water was used as neu-
tralising agent in experiments testing S. aureus, S. epi-
dermidis, E. faecium, and C. albicans. For P. aeruginosa
and S. marcescens, a mixture of 30 g tween 80, 3 g sap-
onin, 1 g histidine, and 1 g of cysteine in 1 l of distilled
water was used. To neutralise CHX lipofundin® MCT
20%, a mixture of soy bean oil, triglycerides, phosphat-
idylcholine, glycerol, α-tocopherol, sodium oleate and
essential fatty acids (B.Braun Melsungen AG) was used.
Results
Test suspensions spread out more evenly on glass test car-
riers and dried faster than on the metal or plastic disc car-
riers. Plastic disc carriers showed two more disadvantages:
the relatively rough surface and the electric charges of
plastic carriers caused the test suspension to form droplets
with prolonged drying time. The uneven spread of the
suspension across the plastic surface resulted in areas with
a particularly high concentration of test bacteria. However,
the recovery of test strains (P. aeruginosa) was better in
plastic and metal carriers, while fewer test strains were re-
coverable from glass carriers. The most favourable test
strain recovery was achieved from metal disc carriers
(Table 1), with losses ranging at only 2 log10. Assessing
these results it should be noted that P. aeruginosa begins
to die off naturally after 3 h after transfer to dried test car-
riers. However, because the applied test solutions covered
the metal disc carries evenly and well, and recovery of test
strains was high, metal carriers were used for all further
experiments.
The standardised test conditions allowed good com-
parison of different antimicrobial compounds with or
without presence of organic soil challenges (Table 2).
Ten percent PVP-I achieved the proposed required
antiseptic efficacy of RF ≥ 5 without and ≥ 3 in the pres-
ence of simulated wound fluid within 5 min against S.
aureus and P. aeruginosa, and against E. faecium within
5 min without and 30 min with organic challenge. Same
results against E. faecium were observed with 0.05%
(after 3 h) and 0.1% (after 30 min) OCT. Against E. fae-
cium, PHMB achieved the required efficacy only at con-
centrations of 0.1 and 0.04%, whereas the lowest use
concentration of 0.02% was not effective within 24 h.
Other tested antiseptics were more effective in the pres-
ence of simulated wound fluid, while blood reduced the
effectiveness of all compounds. Interestingly, a dose/ ex-
posure time depending influence was lowest for OCT;
even at 0.005%, OCT achieved RF ≥ 5 without and ≥ 3 in
the presence of simulated wound fluid within 5 min
against S. aureus and S. epidermidis. However, 0.1% and
0.05% OCT were not as effective against P. aeruginosa as
other tested compounds. In presence of organic soil, CHG
was only effective against P. aeruginosa after 3 h, and per-
formed better against S. aureus and E. faecium. The same
was observed for PHMB, as in presence of soil, higher
concentrations or longer exposure time were needed to
reach a sufficient reduction. The concentration/ exposure
time dependency of PHMB was remarkably seen even
against S. epidermidis, where 0.02% PHMB require 10 h to
be effective, but with higher concentrations the exposure
time decreased sharply (Table 2).
S. marcescens showed the highest tolerability against
the tested antiseptics compared to all other tested bac-
teria. In the presence of organic soil, 0.1% OCT as well
as 0.1% PHMB were not able to achieve reductions at
30 min exposure time. At a concentration of 0.01%
OCT, the required exposure time was increased to 3 h,
and at 0.005% OCT to 10 h (Table 3). C. albicans re-
markable tolerability against tested antiseptics compared
to the tested bacteria. In presence of organic soil, OCT
was effective at concentrations ranging from 0.1 to
0.02%, however, only after an exposure time of 24 h.
Compared to OCT, PHMB showed a better antifungal
efficacy. 0.1% PHMB was effective within 30 min in
presence of organic soil, and at concentration ranging
from 0.04 to 0.02% within 3 up to 10 h.
Discussion
Chronic, and more so, acute wounds always exhibit or-
ganic matter and blood. Therefore, when applying antisep-
tics to wounds, the potentially inhibiting influence of such
organic soil must be considered. In this respect, testing
wound antiseptics without soil seems dispensable. Hence,
Table 1 Recovery of P. aeruginosa from metal, plastic, or glass test carriers
Exposure time
on test carrier
Metal carrier (9.4 log10)
a Log10 difference Plastic carrier (9.5 log10)
a Log10 difference Glass carrier (9.5 log10)
a Log10 difference
5 min 7.8 ± 0.1 1.6 7.9 ± 0.1 1.6 6.7 ± 0.1 2.8
30 min 7.3 ± 0.2 2.1 7.4 ± 0.1 2.1 6.6 ± 0.1 2.9
3 h 7.1 ± 0.1 2.3 7.0 ± 0.4 2.5 6.1 ± 0.2 3.4
aInitial cfu/mL count in the test suspension
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5 min 30 min 3 h 10 h 24 h
10% PVP-I
Without soil - S. aureus 5.4 ± 0.2 5.5 ± 0.1 5.7 ± 0.1 6.0 ± 0.1 4.6 ± 0.5
E. faecium 4.5 ± 0.7 5.1 ± 0.1 5.1 ± 0.1 n.g. n.g.
P. aeruginosa 5.8 ± 1.3 6.3 ± 0.1 6.1 ± 0.1 6.2 ± 0.1 n.g.
MEM + FBS – S. aureus 4.6 ± 0.5 5.1 ± 0.1 5.0 ± 0.1 5.4 ± 0.1 5.5 ± 0.1
E. faecium 4.1 ± 0.6 4.6 ± 0.1 4.2 ± 0.1 n.g. n.g.
P. aeruginosa 4.1 ± 0.4 6.0 ± 0.1 6.1 ± 0.1 n.g. n.g.
CSL+ 30% blood – S. aureus 1.8 ± 0.7 4.2 ± 0.1 5.3 ± 0.1 6.2 ± 0.1 6.5 ± 0.1
E. faecium 1.3 ± 0.2 5.1 ± 0.1 5.1 ± 0.1 n.g. n.g.
P. aeruginosa 2.3 ± 0.4 6.0 ± 0.1 6.1 ± 0.1 n.g. n.g.
0.05% CHG
Without soil - S. aureus 1.6 ± 0.2 3.7 ± 0.3 5.1 ± 0.8 5.8 ± 0.2 6.3 ± 0.1
E. faecium 0.2 ± 0.1 0.6 ± 0.2 1.2 ± 0.2 2.1 ± 0.2 2.6 ± 0.8
P. aeruginosa 0.1 ± 0.2 0.4 ± 0.4 2.1 ± 0.1 4.0 ± 0.7 3.0 ± 0.7
MEM + FBS – S. aureus 2.7 ± 0.4 3.0 ± 0.8 4.7 ± 0.2 5.0 ± 0.3 5.3 ± 0.1
E. faecium 0.5 ± 0.2 2.5 ± 0.4 3.6 ± 0.3 4.0 ± 0.1 4.8 ± 0.1
P. aeruginosa 0.8 ± 0.4 1.0 ± 0.2 5.4 ± 0.1 6.0 ± 0.1 6.6 ± 0.1
CSL+ 30% blood – S. aureus 0.8 ± 0.1 1.3 ± 0.5 3.7 ± 0.4 5.9 ± 0.4 6.7 ± 0.2
E. faecium 0.3 ± 0.5 1.1 ± 0.3 1.8 ± 0.5 3.4 ± 0.7 4.6 ± 0.6
P. aeruginosa 0.1 ± 0.2 1.0 ± 0.3 4.7 ± 1.0 5.8 ± 0.9 7.1 ± 0.1
0.1% OCT
Without soil - S. aureus 4.4 ± 0.1 4.5 ± 0.2 4.6 ± 0.2 5.2 ± 0.1 5.7 ± 0.2
E. faecium 1.5 ± 0.5 2.1 ± 0.4 4.7 ± 1.0 5.6 ± 0.1 5.1 ± 0.1
P. aeruginosa 1.0 ± 0.5 4.8 ± 0.4 4.8 ± 0.4 5.1 ± 0.2 6.2 ± 0.1
MEM + FBS – S. aureus 3.5 ± 0.5 3.4 ± 0.6 3.7 ± 0.6 4.2 ± 0.2 5.4 ± 0.2
E. faecium 2.5 ± 0.5 4.4 ± 0.4 4.4 ± 0.2 4.5 ± 0.3 4.3 ± 0.2
P. aeruginosa 1.1 ± 1.0 3.8 ± 0.3 3.8 ± 0.2 4.2 ± 0.1 5.7 ± 0.1
CSL+ 30% blood – S. aureus 1.2 ± 0.1 2.2 ± 0.1 5.5 ± 0.1 5.8 ± 0.1 5.9 ± 0.1
E. faecium 1.3 ± 0.1 2.6 ± 0.1 5.4 ± 0.1 5.4 ± 0.1 5.4 ± 0.1
P. aeruginosa 0.3 ± 0.1 0.8 ± 0.1 2.2 ± 0.1 6.0 ± 0.1 6.7 ± 0.1
0.05% OCT
Without soil - S. aureus 3.2 ± 1.3 4.5 ± 0.2 4.6 ± 0.2 5.2 ± 0.1 5.7 ± 0.2
E. faecium 1.4 ± 0.3 2.3 ± 0.3 3.4 ± 1.8 5.6 ± 0.1 5.5 ± 0.1
P. aeruginosa 2.1 ± 1.1 4.8 ± 0.4 4.8 ± 0.4 5.5 ± 0.2 6.2 ± 0.1
MEM + FBS – S. aureus 3.5 ± 0.5 3.4 ± 0.6 3.7 ± 0.6 4.2 ± 0.2 5.4 ± 0.2
E. faecium 2.4 ± 1.2 4.4 ± 0.4 4.4 ± 0.2 4.5 ± 0.3 4.3 ± 0.2
P. aeruginosa 1.5 ± 0.1 3.8 ± 0.3 3.8 ± 0.2 4.2 ± 0.1 5.7 ± 0.1
CSL+ 30% blood – S. aureus 1.2 ± 0.1 1.4 ± 0.1 4.6 ± 0.2 5.8 ± 0.1 5.9 ± 0.1
E. faecium 1.1 ± 0.1 2.3 ± 0.1 5.4 ± 0.1 5.4 ± 0.1 5.4 ± 0.1
P. aeruginosa 0.2 ± 0.1 0.8 ± 0.1 1.8 ± 0.1 6.0 ± 0.1 6.7 ± 0.1
0.005% OCT
Without soil – S. aureus 0.8 ± 0.9 4.5 ± 0.2 4.6 ± 0.2 5.2 ± 0.1 5.7 ± 0.2
E. faecium 0.5 ± 0.3 0.7 ± 0.3 1.4 ± 0.7 1.3 ± 0.3 2.9 ± 1.8
Schedler et al. BMC Infectious Diseases  (2017) 17:143 Page 4 of 8
we propose to employ only test conditions in the presence
of soil relevant for wounds for future testing. Based on this
aspect, only the results with organic soil are further dis-
cussed. Yet, not only presence or absence of organic soil
matters, but also the type of organic challenge. Our results
clearly demonstrate the influence of the selected challen-
ging soil in terms of required concentrations or exposure
time of various antiseptics. For instance, if 10% PVP-I is
tested against S. aureus in presence of MEM+ FBS, an ex-
posure time of 5 min is required to achieve a ≥ 3 log10 RF.
However, if the same test is conducted in presence of CSL
+ 30% whole blood, 30 min exposure time are warranted
to achieve the same antimicrobial effect. The same obser-
vation pertains to CHX, OCT, and at lower concentrations
to PHMB (Table 2).
While conducting antimicrobial efficacy tests for
wound antiseptics in presence of organic soil is plausible,
selection of an appropriate organic soil surrogate is not
trivial. Although MEM+ FBS largely corresponds to
physiological wound fluid as proposed by Campbell
Table 2 Mean ± standard deviations log10 RF of different liquid antiseptics with and without organic soil (Continued)
P. aeruginosa 0.4 ± 0.1 1.2 ± 0.4 3.1 ± 1.2 4.7 ± 1.1 5.8 ± 0.8
MEM + FBS – S. aureus 3.1 ± 0.7 3.4 ± 0.6 3.7 ± 0.6 4.2 ± 0.2 5.4 ± 0.2
E. faecium 0.9 ± 0.6 1.5 ± 0.5 2.5 ± 1.2 4.5 ± 0.3 4.3 ± 0.2
P. aeruginosa 0.9 ± 0.5 2.1 ± 1.1 3.8 ± 0.2 4.2 ± 0.1 5.7 ± 0.1
0.1% PHMB
Without soil – S. aureus 2.4 ± 0.1 4.2 ± 0.3 5.4 ± 0.1 5.4 ± 0.1 6.1 ± 0.1
E. faecium 4.8 ± 0.2 5.1 ± 0.1 5.1 ± 0.1 5.2 ± 0.1 5.4 ± 0.1
P. aeruginosa 3.5 ± 0.1 5.5. ± 0.1 5.7 ± 0.1 5.8 ± 0.1 6.0 ± 0.1
MEM + FBS – S. aureus 1.3 ± 0.1 4.2 ± 0.3 5.6 ± 0.1 5.7 ± 0.1 6.1 ± 0.1
E. faecium 4.7 ± 0.3 5.2 ± 0.1 5.4 ± 0.1 5.4 ± 0.1 5.4 ± 0.1
P. aeruginosa 2.4 ± 0.1 5.2 ± 0.2 5.4 ± 0.1 6.1 ± 0.1 6.5 ± 0.1
CSL+ 30% blood – S. aureus 1.1 ± 0.1 1.7 ± 0.1 4.9 ± 0.4 5.8 ± 0.1 5.9 ± 0.1
E. faecium 2.1 ± 0.1 2.1 ± 0.1 4.8 ± 0.3 5.4 ± 0.1 5.4 ± 0.1
P. aeruginosa 0.2 ± 0.1 1.3 ± 0.1 5.8 ± 0.1 6.1 ± 0.1 6.8 ± 0.1
0.04% PHMB
Without soil – S. aureus 1.3 ± 0.1 2.6 ± 0.1 5.1 ± 0.5 5.4 ± 0.1 6.1 ± 0.1
E. faecium 3.8 ± 0.1 5.1 ± 0.1 5.1 ± 0.1 5.2 ± 0.1 5.4 ± 0.1
P. aeruginosa 2.1 ± 0.1 4.5 ± 0.2 5.7 ± 0.1 5.8 ± 0.1 6.0 ± 0.1
MEM + FBS – S. aureus 0.8 ± 0.1 1.2 ± 0.1 5.6 ± 0.1 5.6 ± 0.1 6.1 ± 0.1
E. faecium 3.1 ± 0.1 5.1 ± 0.2 5.4 ± 0.1 5.4 ± 0.1 5.4 ± 0.1
P. aeruginosa 1.0 ± 0.1 3.4 ± 0.1 5.4 ± 0.1 6.1 ± 0.1 6.5 ± 0.1
CSL+ 30% blood – S. aureus 0.9 ± 0.1 1.2 ± 0.1 3.2 ± 0.1 5.8 ± 0.1 5.9 ± 0.1
E. faecium 1.5 ± 0.1 1.5 ± 0.1 2.7 ± 0.1 4.1 ± 0.1 5.4 ± 0.1
P. aeruginosa 0.1 ± 0.1 0.6 ± 0.1 4.1 ± 0.1 6.1 ± 0.1 6.8 ± 0.1
0.02% PHMB
Without soil – S. aureus −0.1 ± 0.1 0.5 ± 0.1 2.8 ± 0.3 5.2 ± 0.1 5.7 ± 0.2
E. faecium 0.3 ± 0.1 0.4 ± 0.2 0.4 ± 0.1 0.2 ± 0.1 0.1 ± 0.1
P. aeruginosa 0.4 ± 0.6 0.2 ± 0.3 1.2 ± 0.8 1.5 ± 0.4 1.4 ± 0.6
MEM + FBS – S. aureus 0.6 ± 0.4 1.7 ± 1.3 3.7 ± 0.6 4.2 ± 0.2 5.4 ± 0.2
E. faecium 0.5 ± 0.2 1.1 ± 0.3 1.1 ± 0.4 1.0 ± 0.9 1.6 ± 0.5
P. aeruginosa 0.5 ± 0.8 0.9 ± 0.1 3.0 ± 1.1 3.2 ± 1.8 3.8 ± 2.1
Controls (test strain: S. aureus)
Gel −0.1 ± 0.2 0.1 ± 0.4 0.3 ± 0.2 0.9 ± 0.3 1.4 ± 0.3
Gel + MEM + FBS 0.1 ± 0.2 0.3 ± 0.3 0.3 ± 0.2 0.8 ± 0.1 1.5 ± 0.6
Distilled watera −0.1 ± 0.2 −0.1 ± 0.2 0.3 ± 0.4 1.0 ± 0.4 1.7 ± 0.6
aControl for aqueous solutions without soil
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et al. previously [5], it does not simulate probable pres-
ence of blood. In addition to MEM+ FBS, we therefore
propose adding 30% blood to simulate a worst-case soil
condition for further testing.
In many parts of the world, PVP-I is one of the most
commonly used wound antiseptics because of its broad
microbial spectrum and rapid onset of action [11–13].
Our results were able to support the view on these as-
pects. Indeed, even in presence of MEM+ FBS, PVP-I
was effective within 5 min against S. aureus, E. faecium,
and P. aeruginosa. Furthermore, when challenged with
30% blood, the required exposure time was extended to
not longer than 30 min. The negative impact of blood
on PVP-I’s antimicrobial efficacy is explained by haemo-
globin’s effect as an inhibitor of the antiseptic effect of
iodine [4, 14]. Free-floating in a liquid environment, this
effect may be even stronger, such as shown by Werner
et al. [15], who used a quantitative suspension test at a
20% blood challenge. If, however, as in conditions
present with the proposed disc carrier test, a sufficiently
high PVP-I concentration is available on a dried surface,
sufficient amounts of free iodine may overcome the
chemical equilibrium, resulting in minimum prolonged
exposure times, increasing from 5 to 30 min for the
same antimicrobial effect. This situation corresponds to
reality much better than in the suspension test because
microbial suspension and antiseptic substance are only
incompletely mixed when applied to the test surface, as
well as to a wound. However, in reality, a mixture of
both conditions may be present, depending on the
Table 3 Required exposure time (h) to achieve a log10 RF≥ 5 (without soil) or log10 RF≥ 3 (with organic soil challenge)
Test compound Soil S. aureus S. epidermidis E. faecium P. aeruginosa S. marcescens C. albicans
10% PVP-I Without 0.0833 Not tested 0.5 0.0833 Not tested Not tested
MEM + FBS 0.0833 0.0833 0.0833
Blood 0.5 0.5 0.5
0.05% CHG Without 3 >24 >24
MEM + FBS 0.5 3 3






Without 10 0.0833 10 10 10 24
10 3 10 10 >24 24
10 3 24 10 >24 >24
10 10 24 10 >24 >24
10 10 >24 10 >24
MEM + FBS 0.0833 0.0833 0.5 0.5 0.5 24
0.0833 0.5 0.5 0.5 0.5 24
0.0833 0.5 0.5 0.5 0.5 >24
0.0833 0.5 0.5 0.5 3 >24
0.0833 0.5 10 0.5 10 >24
Blood 3 n.t. 3 10 n.t. n.t.
3 n.t. 3 10 n.t. n.t.
n.t. n.t. n.t. n.t. n.t. n.t.
n.t. n.t. n.t. n.t. n.t. n.t.




Without 3 0.0833 0.5 0.5 3 10
3 0.0833 0.5 3 10 24
10 >24 >24 >24 >24 >24
MEM + FBS 0.5 0.0833 0.0833 0.5 0.5 3
3 0.0833 0.0833 0.5 3 10
3 10 >24 10 10 >24
Blood 3 n.t. 3 3 n.t. n.t.
3 n.t. 10 3 n.t. n.t.
n.t. n.t. n.t. n.t. n.t. n.t.
n.t. not tested
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exudation grade of a wound. Since PVP-I is character-
ized by good antiseptic and broad-spectrum antimicro-
bial efficacy with low variance of results, it could be
used as reference compound in future for testing the ef-
ficacy of various antiseptics.
Based on our results, CHG, although also frequently
used as an antiseptic globally, would not be a suitable
candidate as reference compound because of its insuffi-
cient efficacy depending on the test species and in pres-
ence of bioburden. Even with the experimental setup
being exactly replicated, the results varied by more than
2.5 log10.
Another suitable candidate would be OCT. In pres-
ence of MEM+ FBS, OCT was bactericidal at concentra-
tions of 0.1% within 5 min, and 0.05% within 30 min,
depending on the test organism. Its efficacy against S.
aureus is comparable to PVP-I, however, against E. fae-
cium and P. aeruginosa, OCT required longer exposure
times ranging between 30 min and 10 h. One of the re-
markable features of OCT is that even when diluted to
0.005%, OCT remains effective against all tested bacteria
after 10 h of exposure time. This corresponds well with
other laboratory-based in-vitro and clinical in-vivo stud-
ies [13, 16, 17]. However, while OCT is widely used in
Germany, Austria and Switzerland [16], it is not well
known yet in many regions of the world.
Finally, PHMB requires longer exposure times than
OCT against most tested microorganisms. This is in ac-
cordance with results obtained in previous quantitative
suspension tests [13]. Low PHMB concentrations of
0.02% and below do not fulfil the antimicrobial require-
ment against E. faecium and C. albicans. However, at
concentrations at 0.04% and if longer exposure times
can be maintained, PHMB exhibits a number of positive
features, including low cytotoxicity and no systemic re-
sorption [18, 19].
One limitation of the here presented phase 2/ step 2
disc carrier test for wound antiseptics is that this test is
not able to assess tissue tolerability. However, such cer-
tainly clinically important aspects are not the primary
aim of a phase 2/ step 2 simulated in-vitro tests. In order
to assess an antimicrobial effect and possible cytotox-
icity, another test, which allows calculation of the “bio-
compatibility index” was presented elsewhere by Müller
and Kramer [17]. Indeed, one reason for the increasing
use of OCT and PHMB for wound antisepsis in Central
Europe is their favourable biocompatibility index of > 1
and the associated lower cytotoxicity in comparison to
PVP-I and CHG [17].
A second limitation pertains to the possibility that test
strains may have reacted differently to drying and that
the recovery from disk carriers considered only viable
strains. However, all tests were comparable in terms of
physical parameters such as drying time, exposure time,
and recovery technique. P. aeruginosa begins to die after
3 h after being transferred to a dry surface. The prepar-
ation time for the test discs and recovery of the viable
bacteria was notably shorter than 3 h. Therefore, a dry-
ing effect did not influence the obtained results of the
recovery rates. Furthermore, since recovery focused on
viable bacteria only in all tests, a possible sampling error
may have occurred, which, however, would have been
distributed evenly through all samples.
In conclusion, this adopted phase 2/ step 2 test
method modified on basis of the EN 14561 by drying
the microbial test suspension on a metal carrier for 1 h,
overlaying the test wound antiseptic, washing-off,
neutralization, and dispersion at serial dilutions at the
end of the required exposure time yielded reproducible,
consistent test results. This method allows testing and
comparing differ liquid and gel based antimicrobial com-
pounds in a standardised setting. Because PVP-I shows a
rapidly deploying, stable antimicrobial effect relatively
independent of external circumstances, it is proposed to
be an ideal candidate used as standard reference in test-
ing wound antiseptics.
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